Show simple item record

dc.contributor.authorSyed, Mohsan Ali
dc.contributor.authorNieder, Carsten
dc.date.accessioned2018-07-24T09:39:21Z
dc.date.available2018-07-24T09:39:21Z
dc.date.issued2017-02-21
dc.description.abstract<p><i>Background</i> Patients with metastatic renal cell carcinoma (mRCC) have variable survival outcomes. When discussing management approaches and providing information to patients and caregivers, it is important to have realistic perspectives, especially if the expected prognosis is very unfavorable. In the present study, factors predicting this endpoint were analyzed.</p> <p><i>Methods</i> Data from 60 patients treated in routine clinical practice were evaluated. Unfavorable prognosis was defined as death within approximately 3 months from diagnosis of mRCC (maximum 3.5 months). Baseline factors including laboratory values and management approach were compared between the groups with short and longer survival.</p> <p><i>Results</i> A total of 48 patients (80%) experienced ≥ 4 months survival (4+MS) and 10 (16.7%) experienced shorter survival (3MS). The others had short follow-up. Adverse prognostic factors that were significantly more frequent in the 3MS group were low hemoglobin, high lactate dehydrogenase and lack of systemic therapy. We used these three items to create a prognostic model: score 0 = no adverse factors, score 1 = one adverse factor, score 2 = two adverse factors, score 3 = three adverse factors. In the score 0 group, one out of 20 patients experienced 3MS (5%). In score 1, two out of 21 patients belonged to the 3MS group (9.5%). For score 2, the corresponding figure was four out of 14 patients (29%). In the score 3 group, three out of three patients experienced 3MS (100%) (P = 0.0001).</p> <p><i>Conclusions</i> A simple model with three prognostic factors predicted survival of patients with newly diagnosed mRCC. Additional validation in other databases is warranted.en_US
dc.descriptionSource at <a href=https://doi.org/10.14740/jocmr2839w> https://doi.org/10.14740/jocmr2839w</a>. Accepted manuscript version, licensed <a href=http://creativecommons.org/licenses/by-nc-nd/4.0/> CC BY-NC-ND 4.0.</a>en_US
dc.identifier.citationSyed, M.A. & Nieder, C. (2017). A Three-Variable Model Predicts Short Survival in Patients With Newly Diagnosed Metastatic Renal Cell Carcinoma. Journal of Clinical Medicine Research, 9(4), 281-288. https://doi.org/10.14740/jocmr2839wen_US
dc.identifier.cristinIDFRIDAID 1544918
dc.identifier.doi10.14740/jocmr2839w
dc.identifier.issn1918-3003
dc.identifier.issn1918-3011
dc.identifier.urihttps://hdl.handle.net/10037/13249
dc.language.isoengen_US
dc.publisherElmer Pressen_US
dc.relation.journalJournal of Clinical Medicine Research
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.subjectKidney canceren_US
dc.subjectMetastatic renal cell carcinomaen_US
dc.subjectPrognostic factorsen_US
dc.subjectPrognostic scoreen_US
dc.subjectSystemic therapyen_US
dc.titleA Three-Variable Model Predicts Short Survival in Patients With Newly Diagnosed Metastatic Renal Cell Carcinomaen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record